https://www.pharmaradar360.com/article/pharmaceutical-society-of-ghana-medical-fraternity-mourn-distinguished-pharmacis-c1d13f9b41e59191Pharma Surgeen2026-07-11T16:17:53.000ZPharmaceutical Society of Ghana, medical fraternity mourn distinguished pharmacist Dr. Samuel Kwasi Nkansahhttps://www.pharmaradar360.com/article/nvidia-ceo-jensen-huang-said-ai-s-most-profound-impact-will-be-in-life-sciences-10865644bbeea8c8Pharma Surgeen2026-07-11T16:14:28.000ZNvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?https://www.pharmaradar360.com/article/nvidia-ceo-jensen-huang-said-ai-s-most-profound-impact-will-be-in-life-sciences-e17c1f426c92bceePharma Surgeen2026-07-11T16:08:12.000ZNvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?https://www.pharmaradar360.com/article/is-the-fda-poised-to-reshape-the-peptide-market-09dec58936fee636Pharma Surgeen2026-07-11T14:20:07.000ZIs the FDA Poised to Reshape the Peptide Markethttps://www.pharmaradar360.com/article/swedbank-ab-makes-new-11-45-million-investment-in-teva-pharmaceutical-industries-d11e7e26dd583c27Pharma Surgeen2026-07-11T14:18:38.000ZSwedbank AB Makes New $11.45 Million Investment in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/maharashtra-fda-bars-sale-of-two-cadila-drugs-over-branding-concerns-5e9eb485b445d35fPharma Surgeen2026-07-11T14:03:00.000ZMaharashtra FDA bars sale of two Cadila drugs over branding concernshttps://www.pharmaradar360.com/article/okyo-pharma-advances-toward-phase-3-fda-trial-icymi-ee230e5505298f01Pharma Surgeen2026-07-11T14:00:00.000ZOKYO Pharma advances toward Phase 3 FDA trial - ICYMIhttps://www.pharmaradar360.com/article/octozi-raises-3-million-seed-to-bring-agentic-ai-into-clinical-trial-data-operat-73538cafeda1dd6dPharma Surgeen2026-07-11T13:53:26.000ZOctozi Raises $3 Million Seed To Bring Agentic AI Into Clinical Trial Data Operationshttps://www.pharmaradar360.com/article/price-to-sales-forward-of-wakamoto-pharmaceutical-co-ltd-tse-4512-44a037b715b4f4f1Pharma Surgeen2026-07-11T13:29:06.000ZPrice to sales forward of Wakamoto Pharmaceutical Co., Ltd. – TSE:4512https://www.pharmaradar360.com/article/equitable-trust-co-invests-2-59-million-in-teva-pharmaceutical-industries-ltd-te-83059a174f577b45Pharma Surgeen2026-07-11T13:02:27.000ZEquitable Trust Co. Invests $2.59 Million in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/gsk-scores-key-win-as-hansoh-s-lung-cancer-drug-meets-phase-iii-survival-goal-1f6a744a7582aeadPharma Surgeen2026-07-11T12:45:47.000ZGSK Scores Key Win as Hansoh's Lung Cancer Drug Meets Phase III Survival Goalhttps://www.pharmaradar360.com/article/strong-biotech-screener-projectsyndicate-indicator-by-projectsyndicate-2f464ede61cc33acPharma Surgeen2026-07-11T12:02:34.000ZStrong Biotech Screener | ProjectSyndicate — Indicator by ProjectSyndicatehttps://www.pharmaradar360.com/article/why-is-sanofi-s-tolebrutinib-facing-a-regulatory-split-941a9c08b59ee378Pharma Surgeen2026-07-11T11:52:23.000ZWhy is Sanofi's Tolebrutinib Facing a Regulatory Splithttps://www.pharmaradar360.com/article/novartis-vs-teva-which-pharmaceutical-stock-is-a-better-buy-in-2026-7a940c7104080a45Pharma Surgeen2026-07-11T11:33:35.000ZNovartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?https://www.pharmaradar360.com/article/kos-pharmaceuticals-in-the-spotlight-as-biotech-gateway-for-greece-8e715c587a22a3efPharma Surgeen2026-07-11T11:22:50.000ZKos Pharmaceuticals in the Spotlight as Biotech Gateway for Greecehttps://www.pharmaradar360.com/article/biotech-stocks-face-big-15b-hit-as-vertex-ionis-skew-flat-weekly-tape-469d4272af0cf581Pharma Surgeen2026-07-11T11:07:10.000ZBiotech Stocks Face Big $15B Hit as Vertex, Ionis Skew Flat Weekly Tapehttps://www.pharmaradar360.com/article/is-edgewise-therapeutics-ewtx-on-the-cusp-of-a-breakthrough-year-62f693b42cd85a30Pharma Surgeen2026-07-11T10:57:49.000ZIs Edgewise Therapeutics (EWTX) on the Cusp of a Breakthrough Yearhttps://www.pharmaradar360.com/article/gel-strength-tester-market-forecast-points-higher-toward-2035-driven-by-pharmace-f5708f0f632fa712Pharma Surgeen2026-07-11T10:36:12.000ZGel Strength Tester Market Forecast Points Higher Toward 2035 Driven by Pharmaceutical Quality Mandateshttps://www.pharmaradar360.com/article/fdaaa-updated-to-include-social-media-in-medication-advertising-45db9008ccdfb50dPharma Surgeen2026-07-11T10:01:00.000ZFDAAA updated to include social media in medication advertisinghttps://www.pharmaradar360.com/article/futura-medical-us-eroxon-deal-and-wsd4000-breakthrough-icymi-707778baa55bfa8cPharma Surgeen2026-07-11T09:38:00.000ZFutura Medical: US Eroxon deal and WSD4000 breakthrough - ICYMIhttps://www.pharmaradar360.com/article/tampa-general-hospital-sues-major-pharmaceutical-company-over-drug-pricing-988749d6df0d399fPharma Surgeen2026-07-11T09:35:46.000ZTampa General Hospital sues major pharmaceutical company over drug pricinghttps://www.pharmaradar360.com/article/why-illinois-patients-need-the-340b-drug-program-opinion-194a36c243085920Pharma Surgeen2026-07-11T08:30:00.000ZWhy Illinois patients need the 340B drug program | Opinionhttps://www.pharmaradar360.com/article/chinese-biotech-mindrank-secures-52m-to-advance-ai-designed-oral-glp-1ra-9a4e968fa90d0bb4Pharma Surgeen2026-07-11T08:01:41.000ZChinese biotech MindRank secures $52m to advance AI-designed oral GLP-1RAhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-emmessar-biotech-nutrition-ltd-bse-emmessa-91757bb9bad2fb34Pharma Surgeen2026-07-11T07:05:54.000ZEnterprise value to EBIT forward of Emmessar Biotech & Nutrition Ltd. – BSE:EMMESSAhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-hunan-warrant-pharmaceutical-co-ltd-class-a-sse-688799-dbbb6c007332616cPharma Surgeen2026-07-11T07:04:34.000ZPrice to sales forward of Hunan Warrant Pharmaceutical Co., Ltd. Class A – SSE:688799https://www.pharmaradar360.com/article/is-viking-therapeutics-poised-to-disrupt-the-weight-loss-market-afb5e819ae6f724ePharma Surgeen2026-07-11T07:00:26.000ZIs Viking Therapeutics Poised to Disrupt the Weight-Loss Markethttps://www.pharmaradar360.com/article/biotech-stock-performance-gap-widens-during-second-quarter-of-2026-bfb36ff8fe1ca4f6Pharma Surgeen2026-07-11T06:19:41.000ZBiotech Stock Performance Gap Widens During Second Quarter of 2026https://www.pharmaradar360.com/article/u-s-biotechs-are-keeping-more-secrets-to-beat-copycats-in-china-dc8d77f710a01a01Pharma Surgeen2026-07-11T05:31:44.000ZU.S. Biotechs Are Keeping More Secrets to Beat Copycats in Chinahttps://www.pharmaradar360.com/article/2-fast-growing-pharmaceutical-stocks-to-buy-now-66c3363883b61229Pharma Surgeen2026-07-11T05:03:44.000Z2 Fast-Growing Pharmaceutical Stocks to Buy Nowhttps://www.pharmaradar360.com/article/sleep-apnea-pill-maker-apnimed-files-for-us-ipo-as-biotech-market-revives-327891e0999d2e6cPharma Surgeen2026-07-11T04:29:15.000ZSleep apnea pill maker Apnimed files for US IPO as biotech market reviveshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-rohto-pharmaceutical-co-ltd-tse-4527-ceaf39dc01c6ced8Pharma Surgeen2026-07-11T02:57:30.000ZPrice to earnings forward of Rohto Pharmaceutical Co., Ltd. – TSE:4527https://www.pharmaradar360.com/article/fda-suspends-kondhwa-cafe-s-licence-for-allegedly-serving-expired-food-products-3b14d221aa52676dPharma Surgeen2026-07-11T02:55:33.000ZFDA suspends Kondhwa cafe’s licence for allegedly serving expired food products | Hindustan Timeshttps://www.pharmaradar360.com/article/phanes-therapeutics-announces-updated-phase-2-clinical-trial-results-of-spevatam-c671cc12b317de93Pharma Surgeen2026-07-11T02:43:49.000ZPhanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meetinghttps://www.pharmaradar360.com/article/biopharma-divides-over-china-response-73c2b967a824c532Pharma Surgeen2026-07-11T02:43:13.000ZBiopharma divides over China responsehttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-kwang-dong-pharmaceutical-co-ltd-krx-009290-f0554c772cd5e8b1Pharma Surgeen2026-07-11T01:30:30.000ZPrice to earnings forward of Kwang Dong Pharmaceutical Co., Ltd. – KRX:009290https://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-sells-smartdose-rights-is-the-stock-fully-price-34650f31521a8a84Pharma Surgeen2026-07-11T01:02:38.000ZWest Pharmaceutical Services (WST) Sells SmartDose Rights, Is The Stock Fully Priced?https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-rtw-biotech-opportunities-ltd-usd-swb-0bm-6dd4bfd95d5de526Pharma Surgeen2026-07-11T00:49:17.000ZEnterprise value to EBITDA forward of RTW Biotech Opportunities Ltd USD – SWB:0BMhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-annji-pharmaceutical-co-ltd-tpex-7754-ed2e720306f46479Pharma Surgeen2026-07-11T00:21:44.000ZPrice to earnings forward of Annji Pharmaceutical Co., Ltd. – TPEX:7754https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-annji-pharmaceutical-co-ltd-tpex-7754-8e52c3b21214ab52Pharma Surgeen2026-07-11T00:09:53.000ZEnterprise value to EBIT forward of Annji Pharmaceutical Co., Ltd. – TPEX:7754https://www.pharmaradar360.com/article/price-to-sales-forward-of-annji-pharmaceutical-co-ltd-tpex-7754-514f64d087bad06aPharma Surgeen2026-07-11T00:06:05.000ZPrice to sales forward of Annji Pharmaceutical Co., Ltd. – TPEX:7754https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-4529d4dea6a8d9b8Pharma Surgeen2026-07-11T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-c2d14adc0827f7dePharma Surgeen2026-07-11T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-1fb30ba33ae12c32Pharma Surgeen2026-07-11T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-469cd3bc860b89c3Pharma Surgeen2026-07-11T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-8074cb74cf32f0a6Pharma Surgeen2026-07-11T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-bb4184ff8e830b5dPharma Surgeen2026-07-11T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-751aec547a673543Pharma Surgeen2026-07-11T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-224601caba673812Pharma Surgeen2026-07-11T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-a3d2aa10606316c7Pharma Surgeen2026-07-11T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-f13424731698e386Pharma Surgeen2026-07-11T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-d97234829c1a3e6cPharma Surgeen2026-07-11T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-4e400d06a6664389Pharma Surgeen2026-07-11T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-7fbfd04e1c760260Pharma Surgeen2026-07-11T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-310a65674b762760Pharma Surgeen2026-07-11T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/anatomical-study-of-the-triangle-of-brocq-and-mouchet-and-its-clinical-implicati-dcc2ece1c6585ba2Pharma Surgeen2026-07-11T00:00:00.000ZAnatomical Study of the Triangle of Brocq and Mouchet and Its Clinical Implications for Coronary Interventions in Human Cadaveric Heartshttps://www.pharmaradar360.com/article/potential-drug-interactions-of-antidiabetic-agents-in-geriatric-patients-with-ty-9254086e4a6c7c5aPharma Surgeen2026-07-11T00:00:00.000ZPotential Drug Interactions of Antidiabetic Agents in Geriatric Patients with Type 2 Diabetes Mellitus at the Inpatient Unit of a Hospital in Bandung Cityhttps://www.pharmaradar360.com/article/a-prospective-observational-study-on-post-operative-pain-and-analgesic-requireme-35a646541e16e654Pharma Surgeen2026-07-11T00:00:00.000ZA Prospective Observational Study on Post-operative Pain and Analgesic Requirementshttps://www.pharmaradar360.com/article/assessment-of-hepatitis-e-virus-seroprevalence-in-patients-presenting-with-suspe-0e8d2999a259ad4dPharma Surgeen2026-07-11T00:00:00.000ZAssessment of Hepatitis E Virus Seroprevalence in Patients Presenting with Suspected Acute Viral Hepatitishttps://www.pharmaradar360.com/article/expression-of-beta-catenin-in-colorectal-carcinoma-an-institutional-study-4273b08ac610263cPharma Surgeen2026-07-11T00:00:00.000ZExpression of Beta-Catenin in Colorectal Carcinoma: An Institutional Studyhttps://www.pharmaradar360.com/article/assessment-of-cervical-cytology-abnormalities-among-reproductive-aged-women-80b3cd1da5b8d819Pharma Surgeen2026-07-11T00:00:00.000ZAssessment of Cervical Cytology Abnormalities Among Reproductive-Aged Womenhttps://www.pharmaradar360.com/article/prevalence-of-premalignant-cervical-lesions-in-histopathological-cervical-biopsi-171707c276309128Pharma Surgeen2026-07-11T00:00:00.000ZPrevalence of Premalignant Cervical Lesions in Histopathological Cervical Biopsieshttps://www.pharmaradar360.com/article/prevalence-and-antibiotic-sensitivity-patterns-of-bacterial-skin-infections-a-cr-20732772cbe9cf26Pharma Surgeen2026-07-11T00:00:00.000ZPrevalence and Antibiotic Sensitivity Patterns of Bacterial Skin Infections: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/assessment-of-immunization-coverage-and-dropout-rates-using-universal-immunizati-7e17cea2b385e144Pharma Surgeen2026-07-11T00:00:00.000ZAssessment of Immunization Coverage and Dropout Rates Using Universal Immunization Programme (UIP) Recordshttps://www.pharmaradar360.com/article/impact-of-treatment-modalities-on-healing-of-tibial-shaft-fractures-8ed3c9f00e773687Pharma Surgeen2026-07-11T00:00:00.000ZImpact of Treatment Modalities on Healing of Tibial Shaft Fractureshttps://www.pharmaradar360.com/article/correlation-of-serum-myeloperoxidase-and-paraoxonase-1-levels-with-atherosclerot-f55086a3dce6c88dPharma Surgeen2026-07-11T00:00:00.000ZCorrelation of Serum Myeloperoxidase and Paraoxonase 1 Levels with Atherosclerotic Risk in Metabolic Syndromehttps://www.pharmaradar360.com/article/a-study-on-isolation-and-identification-of-dermatophytes-among-clinically-suspec-5481adbc872e31fdPharma Surgeen2026-07-11T00:00:00.000ZA Study on Isolation and Identification of Dermatophytes Among Clinically Suspected Cases in A Tertiary Care Center, Patnahttps://www.pharmaradar360.com/article/factors-influencing-laparoscopic-radical-nephrectomy-over-open-nephrectomy-for-l-df182168d4a95b97Pharma Surgeen2026-07-11T00:00:00.000ZFactors Influencing Laparoscopic Radical Nephrectomy Over Open Nephrectomy for Large Renal Tumours (&gt;10 cm): A 16-Year Retrospective Study from a High-Volume Tertiary Centrehttps://www.pharmaradar360.com/article/an-observational-study-on-the-clinical-profile-and-outcomes-of-microbial-keratit-5ec8384ce96d5289Pharma Surgeen2026-07-11T00:00:00.000ZAn Observational Study on the Clinical Profile and Outcomes of Microbial Keratitis in Tertiary Care Hospitalshttps://www.pharmaradar360.com/article/antibiotic-sensitivity-and-resistance-patterns-of-escherichia-coli-isolated-from-565a046366dfe92dPharma Surgeen2026-07-11T00:00:00.000ZAntibiotic Sensitivity and Resistance Patterns of Escherichia coli Isolated from Urinary Tract Infections in Hospitalized Patientshttps://www.pharmaradar360.com/article/comparative-hemodynamic-response-to-spinal-and-epidural-anesthesia-in-lower-abdo-7d3d8ce5fc4bd19cPharma Surgeen2026-07-11T00:00:00.000ZComparative Hemodynamic Response to Spinal and Epidural Anesthesia in Lower Abdominal Surgerieshttps://www.pharmaradar360.com/article/prevalence-and-associated-risk-factors-of-pcos-among-reproductiveaged-women-2f5f1154ce4c1d61Pharma Surgeen2026-07-11T00:00:00.000ZPrevalence and Associated Risk Factors of PCOS Among ReproductiveAged Womenhttps://www.pharmaradar360.com/article/clinical-profile-of-primary-open-angle-glaucoma-patients-age-and-sexwise-compari-c87132a07eac79c5Pharma Surgeen2026-07-11T00:00:00.000ZClinical Profile of Primary Open-Angle Glaucoma Patients: Age and Sexwise Comparison of Visual Field Defectshttps://www.pharmaradar360.com/article/an-observational-study-on-the-classification-risk-factors-and-clinical-managemen-b72505be7cec1368Pharma Surgeen2026-07-11T00:00:00.000ZAn Observational Study on the Classification, Risk Factors, and Clinical Management of Surgical Site Infections in Postoperative Patientshttps://www.pharmaradar360.com/article/retrospective-surveillance-of-candidemia-species-distribution-and-antifungal-sus-d3bfdf5ac4a9c58fPharma Surgeen2026-07-11T00:00:00.000ZRetrospective Surveillance of Candidemia: Species Distribution and Antifungal Susceptibility Patternshttps://www.pharmaradar360.com/article/comparative-analysis-of-dynamic-neuromuscular-stabilization-and-conventional-cor-58df0c0e45398c36Pharma Surgeen2026-07-11T00:00:00.000ZComparative Analysis of Dynamic Neuromuscular Stabilization and Conventional Core Exercises on Core Muscle Weakness and Its Relationship to Chronic Low Back Painhttps://www.pharmaradar360.com/article/targeting-mutant-idh-in-glioma-mechanistic-insights-and-clinical-implications-of-e537921e697bb248Pharma Surgeen2026-07-11T00:00:00.000ZTargeting Mutant IDH in Glioma: Mechanistic Insights and Clinical Implications of Vorasidenibhttps://www.pharmaradar360.com/article/clinical-impact-of-pcsk9-inhibitor-discontinuation-on-cardiovascular-outcomes-re-8e8b0bffa0018e01Pharma Surgeen2026-07-11T00:00:00.000ZClinical Impact of PCSK9 Inhibitor Discontinuation on Cardiovascular Outcomes ― Real-World Evidence From the Kyoto PCSK9 Registry ―https://www.pharmaradar360.com/article/effectiveness-of-gross-s-emotion-regulation-training-on-death-anxiety-in-leukemi-0a9a876d7932714ePharma Surgeen2026-07-11T00:00:00.000ZEffectiveness of Gross’s emotion regulation training on death anxiety in leukemia patients undergoing chemotherapy: a randomized controlled trialhttps://www.pharmaradar360.com/article/evaluating-clinical-heterogeneity-in-relapsing-polychondritis-through-unsupervis-4e6217be295282d6Pharma Surgeen2026-07-11T00:00:00.000ZEvaluating clinical heterogeneity in relapsing polychondritis through unsupervised cluster analysishttps://www.pharmaradar360.com/article/a-mixed-methods-exploration-of-stakeholder-experiences-and-perspectives-on-integ-824b983a04197d08Pharma Surgeen2026-07-11T00:00:00.000ZA mixed-methods exploration of stakeholder experiences and perspectives on integrating polygenic breast cancer risk scores into Swedish clinical practicehttps://www.pharmaradar360.com/article/effects-of-hands-on-breast-self-examination-training-on-knowledge-health-beliefs-d0c379b638a36550Pharma Surgeen2026-07-11T00:00:00.000ZEffects of hands-on breast self-examination training on knowledge, health beliefs, and BSE practice among female university students: a randomized controlled trialhttps://www.pharmaradar360.com/article/linking-vertebral-trabecular-structure-to-growth-rate-clinical-and-developmental-f21c068ccdc91435Pharma Surgeen2026-07-11T00:00:00.000ZLinking vertebral trabecular structure to growth rate: clinical and developmental insightshttps://www.pharmaradar360.com/article/distribution-of-extended-spectrum-lactamases-blashv-blatem-blactx-m-and-ampc-lac-ca813462188b1585Pharma Surgeen2026-07-11T00:00:00.000ZDistribution of extended-spectrum β-lactamases (blaSHV, blaTEM, blaCTX-M) and AmpC β-lactamases -encoding genes among second- and third-generation cephalosporin-resistant Escherichia coli clinical isolates in Sana’a, Yemenhttps://www.pharmaradar360.com/article/association-between-perceived-quality-of-postoperative-pain-care-and-patient-rep-23ea3126e7bc2f82Pharma Surgeen2026-07-11T00:00:00.000ZAssociation Between Perceived Quality of Postoperative Pain Care and Patient‐Reported Outcomes After Total Knee or Total Hip Arthroplasty: A Cross‐Sectional Studyhttps://www.pharmaradar360.com/article/clinical-radiographic-and-patient-centred-outcomes-of-scp-minst-scp-versus-scp-m-59c59e8fef3ba7d9Pharma Surgeen2026-07-11T00:00:00.000ZClinical, Radiographic and Patient‐Centred Outcomes of <scp>MINST</scp> Versus <scp>MIST</scp> With Enamel Matrix Derivative in Class <scp>II</scp> Mandibular Furcation Defects: A Randomised Controlled Trialhttps://www.pharmaradar360.com/article/user-satisfaction-with-fingerstick-versus-continuous-glucose-monitoring-in-surgi-4171f60e5003840ePharma Surgeen2026-07-11T00:00:00.000ZUser satisfaction with fingerstick versus continuous glucose monitoring in surgical wards: A two‐centre non‐randomised clinical trialhttps://www.pharmaradar360.com/article/chronic-kidney-disease-outcomes-in-patients-treated-with-immune-checkpoint-inhib-23869d0ab0fab5a7Pharma Surgeen2026-07-11T00:00:00.000ZChronic Kidney Disease Outcomes in Patients Treated with Immune Checkpoint Inhibitorshttps://www.pharmaradar360.com/article/clinical-controversies-in-the-management-of-candidemia-in-adults-and-children-f49f3824c8b4203aPharma Surgeen2026-07-11T00:00:00.000ZClinical controversies in the management of candidemia in adults and childrenhttps://www.pharmaradar360.com/article/effects-of-intraoperative-low-dose-remimazolam-maintenance-on-emergence-agitatio-c0c04168a37fa7f1Pharma Surgeen2026-07-11T00:00:00.000ZEffects of intraoperative low-dose remimazolam maintenance on emergence agitation and emergence time in patients undergoing oral surgery: protocol for a randomized controlled trialhttps://www.pharmaradar360.com/article/presidential-support-for-drug-policy-reform-a-comparison-of-cannabis-policies-in-290276d44871d569Pharma Surgeen2026-07-11T00:00:00.000ZPresidential support for drug policy reform: a comparison of cannabis policies in Argentina, Chile and Uruguay (1973–2015)https://www.pharmaradar360.com/article/mapping-artificial-intelligence-integration-in-objective-structured-clinical-exa-275c96ef4b3cdf2bPharma Surgeen2026-07-11T00:00:00.000ZMapping artificial intelligence integration in objective structured clinical examinations: A scoping reviewhttps://www.pharmaradar360.com/article/the-role-of-spousal-relationships-in-shaping-clinical-trajectories-during-aging-736284ef0bad526dPharma Surgeen2026-07-11T00:00:00.000ZThe role of spousal relationships in shaping clinical trajectories during aginghttps://www.pharmaradar360.com/article/duration-of-belimumab-therapy-and-timing-of-initiation-as-predictors-of-clinical-81a9872e927cf445Pharma Surgeen2026-07-11T00:00:00.000ZDuration of Belimumab Therapy and Timing of Initiation as Predictors of Clinical Outcomes in Childhood-Onset Systemic Lupus Erythematosus: A Real-World Retrospective Studyhttps://www.pharmaradar360.com/article/intrinsic-capacity-and-comorbidity-burden-capture-distinct-but-age-driven-dimens-f3e2637be5689f0bPharma Surgeen2026-07-11T00:00:00.000ZIntrinsic capacity and comorbidity burden capture distinct but age-driven dimensions of health in older postmenopausal womenhttps://www.pharmaradar360.com/article/valproic-acid-e6c1382aa1358552Pharma Surgeen2026-07-11T00:00:00.000ZValproic acidhttps://www.pharmaradar360.com/article/colchicine-31f7ffe0767fddb9Pharma Surgeen2026-07-11T00:00:00.000ZColchicinehttps://www.pharmaradar360.com/article/co-creation-of-the-epicom-clinical-trial-bringing-the-tuberous-sclerosis-complex-c379d8c5a3956aa4Pharma Surgeen2026-07-11T00:00:00.000ZCo-Creation of the EpiCom Clinical Trial: Bringing the Tuberous Sclerosis Complex Patient Community, Healthcare Professionals, and the Pharmaceutical Industry Togetherhttps://www.pharmaradar360.com/article/copper-deficiency-anemia-and-neutropenia-during-zinc-maintenance-therapy-for-wil-7e73dd910e286750Pharma Surgeen2026-07-11T00:00:00.000ZCopper-deficiency anemia and neutropenia during zinc maintenance therapy for Wilson disease associated with persistent strict dietary copper restrictionhttps://www.pharmaradar360.com/article/fusobacterium-nucleatum-succinate-signaling-and-immunotherapy-resistance-in-colo-74e5cbaa866b031bPharma Surgeen2026-07-11T00:00:00.000ZFusobacterium nucleatum, succinate signaling, and immunotherapy resistance in colorectal cancer: clinical relevance and translational opportunitieshttps://www.pharmaradar360.com/article/post-trial-obligations-and-participant-enrollment-in-brain-pioneering-research-s-3aa62e84309d2c4ePharma Surgeen2026-07-11T00:00:00.000ZPost-trial obligations and participant enrollment in brain pioneering research: should we expand inclusion criteria?https://www.pharmaradar360.com/article/a-digital-cueing-intervention-for-parkinsonian-gait-laboratory-based-clinical-va-ee04d2a8b89d9b9aPharma Surgeen2026-07-11T00:00:00.000ZA Digital Cueing Intervention for Parkinsonian Gait: Laboratory-Based Clinical Validation and Acute Gait Responseshttps://www.pharmaradar360.com/article/clinical-management-of-vestibular-schwannoma-what-s-the-evidence-45eab166a734dae9Pharma Surgeen2026-07-11T00:00:00.000ZClinical management of vestibular schwannoma – what’s the evidence?https://www.pharmaradar360.com/article/correction-distinguishing-reactive-scoliosis-clinical-presentation-pathophysiolo-1036761853f0708fPharma Surgeen2026-07-11T00:00:00.000ZCorrection: Distinguishing reactive scoliosis: clinical presentation, pathophysiology and a proposed clinical frameworkhttps://www.pharmaradar360.com/article/characteristics-of-patients-with-epithelioid-hemangioendothelioma-ehe-a-retrospe-cf98f34d9bd0d95fPharma Surgeen2026-07-11T00:00:00.000ZCharacteristics of patients with epithelioid hemangioendothelioma (EHE): a retrospective analysis of the Charité- Universitätsmedizin Berlinhttps://www.pharmaradar360.com/article/edi-oct-detection-of-sub-tenon-s-fluid-in-posterior-scleritis-in-myopic-eyes-a-r-00868569159e12fcPharma Surgeen2026-07-11T00:00:00.000ZEDI-OCT detection of sub-Tenon’s fluid in posterior scleritis in myopic eyes: a retrospective case serieshttps://www.pharmaradar360.com/article/pharmacogenomic-screening-strategy-and-indicative-screening-efficiency-for-antit-eed5801d7ef44eb2Pharma Surgeen2026-07-11T00:00:00.000ZPharmacogenomic screening strategy and indicative screening efficiency for antithyroid drug-induced agranulocytosis in the Southern Han Chinesehttps://www.pharmaradar360.com/article/pragmatic-clinical-trial-of-fostamatinib-as-second-line-therapy-in-adult-patient-843ddb9567bbaff2Pharma Surgeen2026-07-11T00:00:00.000ZPragmatic Clinical Trial of Fostamatinib as Second‐Line Therapy in Adult Patients With Immune Thrombocytopenia and Insufficient Response to Prior Therapy: The Fostamatinib FORTE Trialhttps://www.pharmaradar360.com/article/complete-lesion-resection-and-early-surgical-intervention-are-favorable-factors-f870fe27da41e338Pharma Surgeen2026-07-11T00:00:00.000ZComplete lesion resection and early surgical intervention are favorable factors for long‐term seizure freedom in drug‐resistant epileptic spasmshttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-annji-pharmaceutical-co-ltd-tpex-7754-44a465915959d6a2Pharma Surgeen2026-07-10T23:50:57.000ZEnterprise value to revenue forward of Annji Pharmaceutical Co., Ltd. – TPEX:7754https://www.pharmaradar360.com/article/sleep-apnea-pill-maker-apnimed-files-for-us-ipo-as-biotech-market-revives-42d4de2b0191c564Pharma Surgeen2026-07-10T23:02:53.000ZSleep apnea pill maker Apnimed files for US IPO as biotech market reviveshttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32Pharma Surgeen2026-07-10T22:54:54.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/etfs-investing-in-hunan-warrant-pharmaceutical-co-ltd-class-a-stocks-8bfd769148acdf30Pharma Surgeen2026-07-10T22:50:50.000ZETFs Investing in Hunan Warrant Pharmaceutical Co., Ltd. Class A Stockshttps://www.pharmaradar360.com/article/landmark-clinical-trial-results-in-first-fda-approved-treatment-for-rare-form-of-d8c33ad5704fae1cPharma Surgeen2026-07-10T22:50:00.000ZLandmark Clinical Trial Results in First FDA-Approved Treatment for Rare Form of Obesity Caused by Brain Injury | Newswisehttps://www.pharmaradar360.com/article/two-preventable-semaglutide-dosing-errors-may-have-driven-a-surge-in-poison-cont-e065838f9ec3b918Pharma Surgeen2026-07-10T22:35:09.000ZTwo Preventable Semaglutide Dosing Errors May Have Driven a Surge in Poison Control Callshttps://www.pharmaradar360.com/article/can-m-a-momentum-carry-biotech-through-year-end-badbda538376d63fPharma Surgeen2026-07-10T22:06:00.000ZCan M&A momentum carry biotech through year-end?https://www.pharmaradar360.com/article/is-this-biotech-stock-a-buy-near-its-52-week-high-c593a0e5bf2a9573Pharma Surgeen2026-07-10T22:00:00.000ZIs This Biotech Stock a Buy Near Its 52-Week High?https://www.pharmaradar360.com/article/us-fda-proposes-one-registration-for-distributed-drug-manufacturing-networks-210e28a7b31d586dPharma Surgeen2026-07-10T21:50:48.000ZUS FDA Proposes One Registration For Distributed Drug Manufacturing Networkshttps://www.pharmaradar360.com/article/is-this-biotech-stock-a-buy-near-its-52-week-high-adb2f57085c6fadcPharma Surgeen2026-07-10T21:20:00.000ZIs This Biotech Stock a Buy Near Its 52-Week High?https://www.pharmaradar360.com/article/west-pharmaceutical-services-inc-stock-underperforms-friday-when-compared-to-com-0d9ba41beec303eePharma Surgeen2026-07-10T21:02:00.000ZWest Pharmaceutical Services Inc. stock underperforms Friday when compared to competitorshttps://www.pharmaradar360.com/article/roche-ends-both-huntington-s-disease-drug-programs-after-biomarkers-beat-patient-44c48e967fe4395aPharma Surgeen2026-07-10T21:00:06.000ZRoche Ends Both Huntington’s Disease Drug Programs After Biomarkers Beat Patientshttps://www.pharmaradar360.com/article/partnership-for-safe-medicines-urges-fda-advisory-committee-to-reject-compoundin-6cbe262045a3a05aPharma Surgeen2026-07-10T20:57:36.000ZPartnership for Safe Medicines urges FDA advisory committee to reject compounding of unapproved peptideshttps://www.pharmaradar360.com/article/biotech-stocks-are-projected-to-extend-rally-amid-innovation-and-m-a-539b0583484df912Pharma Surgeen2026-07-10T20:33:33.000ZBiotech Stocks Are Projected to Extend Rally Amid Innovation and M&Ahttps://www.pharmaradar360.com/article/is-there-a-semaglutide-shortage-ozempic-and-wegovy-availability-updates-d7e84f88850e7ac6Pharma Surgeen2026-07-10T20:24:20.000ZIs There A Semaglutide Shortage? Ozempic and Wegovy Availability Updateshttps://www.pharmaradar360.com/article/fda-to-rule-july-17-on-gedatolisib-first-targeted-therapy-for-pik3ca-wild-type-b-f0760befc854ceb6Pharma Surgeen2026-07-10T20:19:37.000ZFDA to Rule July 17 on Gedatolisib, First Targeted Therapy for PIK3CA Wild-Type Breast Cancerhttps://www.pharmaradar360.com/article/5-glp-1-trends-to-expect-in-2026-expanded-uses-oral-options-and-more-a72fa01a22fd1a9bPharma Surgeen2026-07-10T20:18:00.000Z5 GLP-1 Trends to Expect in 2026: Expanded Uses, Oral Options, and Morehttps://www.pharmaradar360.com/article/fda-s-rule-seeks-to-modernize-drug-manufacturing-registration-e158a2eafe0acc85Pharma Surgeen2026-07-10T20:15:44.000ZFDA’s rule seeks to modernize drug manufacturing registrationhttps://www.pharmaradar360.com/article/why-this-pharmaceutical-stock-jumped-close-to-100-this-week-a66c8288f691d509Pharma Surgeen2026-07-10T20:02:00.000ZWhy This Pharmaceutical Stock Jumped Close to 100% This Weekhttps://www.pharmaradar360.com/article/fda-proposes-rule-to-simplify-drug-manufacturing-registration-cc818d0b9772c30fPharma Surgeen2026-07-10T19:46:59.000ZFDA Proposes Rule To Simplify Drug Manufacturing Registrationhttps://www.pharmaradar360.com/article/fda-proposes-drug-registration-changes-to-boost-supply-chain-transparency-5df929d0fcae5818Pharma Surgeen2026-07-10T19:38:55.000ZFDA proposes drug registration changes to boost supply chain transparencyhttps://www.pharmaradar360.com/article/us-fda-proposes-rule-to-simplify-registration-for-some-drug-manufacturers-d4b1db0e9094de4ePharma Surgeen2026-07-10T19:37:05.000ZUS FDA proposes rule to simplify registration for some drug manufacturershttps://www.pharmaradar360.com/article/why-this-pharmaceutical-stock-jumped-close-to-100-this-week-9d39b260a4a9cf45Pharma Surgeen2026-07-10T19:22:32.000ZWhy This Pharmaceutical Stock Jumped Close to 100% This Weekhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-sells-smartdose-rights-to-abbvie-to-refocus-its-8be50952b00a33f3Pharma Surgeen2026-07-10T19:11:51.000ZWest Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its Businesshttps://www.pharmaradar360.com/article/korea-s-hlb-fails-to-win-fda-approval-on-liver-cancer-drug-for-3rd-time-stocks-h-f5abed863ccf3cdbPharma Surgeen2026-07-10T19:05:06.000ZKorea’s HLB fails to win FDA approval on liver cancer drug for 3rd time; stocks hit 9-month lowhttps://www.pharmaradar360.com/article/keeping-pace-with-generative-ai-in-pharmaceutical-and-healthcare-organisations-ecd782410162b497Pharma Surgeen2026-07-10T18:41:40.000ZKeeping pace with generative AI in pharmaceutical and healthcare organisationshttps://www.pharmaradar360.com/article/outsourcing-formulation-activities-may-advance-drug-development-5944d75d5ad4da59Pharma Surgeen2026-07-10T18:18:54.000ZOutsourcing Formulation Activities May Advance Drug Developmenthttps://www.pharmaradar360.com/article/abbott-labs-vs-danaher-abbott-s-everyday-products-beat-danaher-s-slumping-biotec-1b9767ba197f331aPharma Surgeen2026-07-10T18:18:48.000ZAbbott Labs Vs. Danaher: Abbott’s Everyday Products Beat Danaher’s Slumping Biotech Equipmenthttps://www.pharmaradar360.com/article/chinese-biotech-taking-early-phase-precision-medicine-trials-to-australia-amid-u-100ce4c715f9e9a8Pharma Surgeen2026-07-10T18:16:23.000ZChinese Biotech Taking Early-Phase Precision Medicine Trials to Australia Amid US Restrictionshttps://www.pharmaradar360.com/article/fda-approves-keytruda-pembrolizumab-and-keytruda-qlextm-pembrolizumab-and-berahy-e5ca02689e4cee46Pharma Surgeen2026-07-10T18:10:00.000ZFDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)https://www.pharmaradar360.com/article/fda-s-crl-disclosure-freeze-and-dtc-ad-crackdown-likely-headed-for-court-sue-sut-59ef9dea0fd39ff9Pharma Surgeen2026-07-10T18:09:00.000ZFDA's CRL Disclosure Freeze and DTC Ad Crackdown Likely Headed for Court, Sue Sutter and Derrick Gingery Warnhttps://www.pharmaradar360.com/article/sanofi-wins-fda-approval-for-wearable-injector-form-of-blood-cancer-drug-bd07db00c233482aPharma Surgeen2026-07-10T18:00:58.000ZSanofi Wins FDA Approval for Wearable Injector Form of Blood Cancer Drughttps://www.pharmaradar360.com/article/cder-proposes-to-withdraw-approval-of-tavneos-a685cf2b34395291Pharma Surgeen2026-07-10T17:58:31.000ZCDER proposes to withdraw approval of TAVNEOShttps://www.pharmaradar360.com/article/fda-clears-phase-ii-trial-for-rare-skin-disorder-drug-ffbbd9279f88fdb2Pharma Surgeen2026-07-10T17:57:03.000ZFDA clears Phase II trial for rare skin disorder drughttps://www.pharmaradar360.com/article/vertex-is-paying-a-102-premium-to-acquire-crinetics-for-10-billion-here-s-whethe-856e83a2b873df24Pharma Surgeen2026-07-10T17:53:31.000ZVertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.https://www.pharmaradar360.com/article/fda-rejects-hengrui-elevar-liver-cancer-drug-combo-for-third-time-5156a6523a425804Pharma Surgeen2026-07-10T17:42:00.000ZFDA rejects Hengrui-Elevar liver cancer drug combo for third timehttps://www.pharmaradar360.com/article/nmpa-in-china-approves-heng-yi-cyclosporine-drop-35590619abc9e1eePharma Surgeen2026-07-10T17:38:15.000ZNMPA in China approves Heng Yi cyclosporine drophttps://www.pharmaradar360.com/article/recursion-pharmaceuticals-stock-rxrx-opinions-on-biotech-ai-prospects-33f506a65f51ccfbPharma Surgeen2026-07-10T17:37:00.000ZRecursion Pharmaceuticals Stock (RXRX) Opinions on Biotech AI Prospectshttps://www.pharmaradar360.com/article/fda-approves-subcutaneous-sarclisa-escena-pharmexec-04f989387fdda59dPharma Surgeen2026-07-10T17:22:30.000ZFDA Approves Subcutaneous Sarclisa Escena | PharmExechttps://www.pharmaradar360.com/article/regenxbio-doses-first-patient-in-phase-2b-3-trial-for-dr-b2ce5cd304f8c00dPharma Surgeen2026-07-10T17:22:18.000ZRegenxBio doses first patient in phase 2b/3 trial for DRhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-tse-4502-taps-pharma-ai-for-drug-discovery-is-the-stock-st-2a494b8e384dacadPharma Surgeen2026-07-10T17:02:15.000ZTakeda Pharmaceutical (TSE:4502) Taps Pharma.AI For Drug Discovery, Is The Stock Still Cheap?https://www.pharmaradar360.com/article/ministers-launch-crackdown-on-vapes-targeting-kids-a8ae5b715136ed83Pharma Surgeen2026-07-10T16:58:57.000ZMinisters launch crackdown on vapes targeting kidshttps://www.pharmaradar360.com/article/bhiwandi-food-safety-drive-bncmc-fda-to-crack-down-on-illegal-food-businesses-af-0cc1fb8242ec2751Pharma Surgeen2026-07-10T16:58:18.000ZBhiwandi Food Safety Drive: BNCMC, FDA To Crack Down On Illegal Food Businesses After Mass Food Poisoninghttps://www.pharmaradar360.com/article/fda-pauses-real-time-release-of-drug-rejection-letters-while-working-to-formaliz-e13ca09a939c7d29Pharma Surgeen2026-07-10T16:45:55.000ZFDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policyhttps://www.pharmaradar360.com/article/keeping-pace-with-generative-ai-in-pharmaceutical-and-healthcare-organisations-bd38fbf1a343fea7Pharma Surgeen2026-07-10T16:17:19.000ZKeeping pace with generative AI in pharmaceutical and healthcare organisationshttps://www.pharmaradar360.com/article/weekly-buzz-jnj-vera-get-fda-nod-vrtx-snaps-up-crnx-msle-aces-dmd-trial-ions-mis-d0b3edd28ef47bbbPharma Surgeen2026-07-10T16:10:00.000ZWeekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goalhttps://www.pharmaradar360.com/article/biotech-stocks-to-keep-an-eye-on-july-10th-b6a6287e600dc440Pharma Surgeen2026-07-10T16:05:54.000ZBiotech Stocks To Keep An Eye On - July 10thhttps://www.pharmaradar360.com/article/moderna-drops-11-immunitybio-and-sarepta-therapeutics-tumble-8-in-biotech-rout-f6aa6966d6e50111Pharma Surgeen2026-07-10T16:04:38.000ZModerna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Routhttps://www.pharmaradar360.com/article/pharmaceutical-marketplaces-how-online-platforms-are-changing-drug-purchasing-ee531ff4405b2912Pharma Surgeen2026-07-10T16:00:35.000ZPharmaceutical marketplaces: How online platforms are changing drug purchasinghttps://www.pharmaradar360.com/article/hlb-hengrui-receive-third-us-fda-rejection-on-liver-cancer-combo-0ad9525699d3ec08Pharma Surgeen2026-07-10T16:00:00.000ZHLB, Hengrui receive third US FDA rejection on liver cancer combohttps://www.pharmaradar360.com/article/we-re-paranoid-as-china-biotech-competition-heats-up-american-drugmakers-get-mor-f3874797eb7fc888Pharma Surgeen2026-07-10T16:00:00.000Z'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretivehttps://www.pharmaradar360.com/article/ab-science-provides-an-update-on-its-clinical-program-suspending-some-non-priori-4d3c804f6162edf6Pharma Surgeen2026-07-10T15:49:00.000ZAB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programshttps://www.pharmaradar360.com/article/daito-pharmaceutical-co-ltd-announces-an-equity-buyback-for-500-000-shares-repre-eb2d0b49aeb18cdbPharma Surgeen2026-07-10T15:42:55.000ZDaito Pharmaceutical Co.,Ltd. announces an Equity Buyback for 500,000 shares, representing 1.73% for ¥625 million.https://www.pharmaradar360.com/article/the-benefits-of-physical-activity-at-all-stages-of-life-for-health-ce307e392e7da498Pharma Surgeen2026-07-10T15:42:21.000ZThe benefits of physical activity at all stages of life for healthhttps://www.pharmaradar360.com/article/big-changes-ahead-for-oregon-s-psilocybin-agency-new-bill-seeks-to-turn-trump-s-10728931548038fbPharma Surgeen2026-07-10T15:31:49.000ZBig changes ahead for Oregon’s psilocybin agency, New bill seeks to turn Trump’s psychedelics executive order into permanent lawhttps://www.pharmaradar360.com/article/fda-seeks-simpler-drug-site-registration-43196f4aafa21924Pharma Surgeen2026-07-10T15:26:23.000ZFDA Seeks Simpler Drug Site Registrationhttps://www.pharmaradar360.com/article/us-fda-proposes-rule-to-simplify-registration-for-some-distributed-drug-manufact-1bb97abb879c2bf3Pharma Surgeen2026-07-10T15:24:12.000ZUS FDA proposes rule to simplify registration for some distributed drug manufacturershttps://www.pharmaradar360.com/article/as-neoadjuvant-and-adjuvant-treatment-for-muscle-invasive-bladder-cancer-regardl-d899fc5fb932f6dbPharma Surgeen2026-07-10T15:23:00.000Zas Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibilityhttps://www.pharmaradar360.com/article/cathay-cargo-points-to-new-pharma-market-opportunities-fc5d1669fd0ed68dPharma Surgeen2026-07-10T15:09:03.000ZCathay Cargo points to new pharma market opportunitieshttps://www.pharmaradar360.com/article/fda-proposes-rule-to-modernize-drug-manufacturing-registration-b7efaf004d60e7e0Pharma Surgeen2026-07-10T15:01:45.000ZFDA Proposes Rule to Modernize Drug Manufacturing Registrationhttps://www.pharmaradar360.com/article/fda-expands-pembrolizumab-label-for-muscle-invasive-bladder-cancer-5899cc6796aebc0ePharma Surgeen2026-07-10T14:52:52.000ZFDA Expands Pembrolizumab Label for Muscle-Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/the-future-looks-bright-for-biotechnology-companies-investments-to-buy-ecee00ad879b9e4cPharma Surgeen2026-07-10T14:42:57.000ZThe future looks bright for biotechnology companies – investments to buyhttps://www.pharmaradar360.com/article/hansoh-meets-phase-3-sclc-goal-fda-approves-sanofi-on-body-injector-2213f2916ca8aae6Pharma Surgeen2026-07-10T14:35:00.000ZHansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injectorhttps://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-06111ba867dc3c23Pharma Surgeen2026-07-10T14:29:47.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/bayer-banks-3bn-in-apollo-contraceptives-division-deal-514399e57bc89f3bPharma Surgeen2026-07-10T14:16:37.000ZBayer banks €3bn in Apollo contraceptives division dealhttps://www.pharmaradar360.com/article/how-pbm-reform-is-reshaping-the-operational-environment-for-pharma-manufacturers-0d9cccdf833500caPharma Surgeen2026-07-10T14:03:24.000ZHow PBM Reform Is Reshaping the Operational Environment for Pharma Manufacturershttps://www.pharmaradar360.com/article/fda-neurology-roundup-june-2026-eb8db04178f88dcePharma Surgeen2026-07-10T13:57:00.000ZFDA Neurology Roundup: June 2026https://www.pharmaradar360.com/article/trial-of-fast-tracked-new-parkinson-s-cell-therapy-hits-critical-step-0f5d80406cce13b3Pharma Surgeen2026-07-10T13:52:32.000ZTrial of fast-tracked new Parkinson’s cell therapy hits ‘critical’ stephttps://www.pharmaradar360.com/article/how-tailormed-tennr-aim-to-speed-specialty-access-ccd797685e30cdc4Pharma Surgeen2026-07-10T13:38:24.000ZHow TailorMed, Tennr Aim to Speed Specialty Accesshttps://www.pharmaradar360.com/article/roche-ends-huntington-s-gene-silencing-programs-064c9dc615acda95Pharma Surgeen2026-07-10T13:37:14.000ZRoche ends Huntington’s gene-silencing programshttps://www.pharmaradar360.com/article/europe-s-drug-price-controls-are-undercutting-american-leadership-2fd1e26f0510a039Pharma Surgeen2026-07-10T13:25:32.000ZEurope's Drug Price Controls Are Undercutting American Leadershiphttps://www.pharmaradar360.com/article/sanofi-snags-fda-thumbs-up-for-sarclisa-as-1st-cancer-drug-delivered-by-on-body-7c2102d94755a1a9Pharma Surgeen2026-07-10T13:18:21.000ZSanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injectorhttps://www.pharmaradar360.com/article/akston-biosciences-opening-on-kings-highway-next-month-with-70-jobs-at-100k-sala-ef358567b87f6d9dPharma Surgeen2026-07-10T13:11:51.000ZAkston Biosciences Opening On Kings Highway Next Month With 70 Jobs At $100K Salarieshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-rtw-biotech-opportunities-ltd-usd-swb-0bm-4b0134b1e616da61Pharma Surgeen2026-07-10T13:01:23.000ZPrice to earnings forward of RTW Biotech Opportunities Ltd USD – SWB:0BMhttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-20-report-data-to-week-19-dat-eb9151086d6e9097Pharma Surgeen2026-07-10T12:53:50.000ZNational flu and COVID-19 surveillance report, week 20 report: data to week 19 (data up to 16 May 2027)https://www.pharmaradar360.com/article/fierce-pharma-asia-more-az-china-deals-kailera-hengrui-s-oral-glp-1-data-scrutin-f16d101eb0bb05bcPharma Surgeen2026-07-10T12:51:21.000ZFierce Pharma Asia—More AZ China deals; Kailera, Hengrui’s oral GLP-1 data; Scrutiny of Chinese trialshttps://www.pharmaradar360.com/article/fda-finds-trace-metals-in-tampons-but-says-products-remain-safe-f38dd5aa7d460188Pharma Surgeen2026-07-10T12:44:21.000ZFDA Finds Trace Metals in Tampons but Says Products Remain Safehttps://www.pharmaradar360.com/article/guidance-medicines-that-you-cannot-export-from-the-uk-or-hoard-b8bd1378944b2e76Pharma Surgeen2026-07-10T12:30:33.000ZGuidance: Medicines that you cannot export from the UK or hoardhttps://www.pharmaradar360.com/article/annovis-bio-completes-enrollment-for-pivotal-phase-3-alzheimer-s-trial-plans-nda-763a1e280dcf7e6bPharma Surgeen2026-07-10T12:27:00.000ZAnnovis Bio Completes Enrollment for Pivotal Phase 3 Alzheimer’s Trial, Plans NDA Submissions in 2027 and 2028 12https://www.pharmaradar360.com/article/biotech-stocks-at-52-week-highs-trax-bbio-mnpr-txg-mplt-6f0e8c441c8723e3Pharma Surgeen2026-07-10T12:17:00.000ZBiotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLThttps://www.pharmaradar360.com/article/roche-scraps-2-huntington-s-studies-handing-ionis-more-bad-news-6299bc720455d3cbPharma Surgeen2026-07-10T12:04:06.000ZRoche scraps 2 Huntington’s studies, handing Ionis more bad newshttps://www.pharmaradar360.com/article/here-s-why-shares-in-novo-nordisk-rival-agios-pharmaceutical-soared-this-week-53e0b6b1bc74e95bPharma Surgeen2026-07-10T12:03:03.000ZHere's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Weekhttps://www.pharmaradar360.com/article/new-australian-patent-backs-klotho-gene-therapy-targeting-als-and-other-neuromus-61dbd440d1113d91Pharma Surgeen2026-07-10T12:00:00.000ZNew Australian patent backs Klotho gene therapy targeting ALS and other neuromuscular diseaseshttps://www.pharmaradar360.com/article/biotech-ceo-on-new-novo-nordisk-partnership-this-could-be-big-257a9d0501ab1bc2Pharma Surgeen2026-07-10T11:59:00.000ZBiotech CEO on new Novo Nordisk partnership: “This could be big”https://www.pharmaradar360.com/article/daito-pharmaceutical-co-ltd-provides-consolidated-earnings-guidance-for-the-year-df5b07e1a0ef4ab5Pharma Surgeen2026-07-10T11:51:05.000ZDaito Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Year Ending May 31, 2027https://www.pharmaradar360.com/article/meningococcal-b-menb-time-limited-vaccination-offer-c40ee43363d9a479Pharma Surgeen2026-07-10T11:49:20.000ZMeningococcal B (MenB) time limited vaccination offerhttps://www.pharmaradar360.com/article/chinese-biotech-mindrank-secures-52m-to-advance-ai-designed-oral-glp-1ra-26ca676189430a2cPharma Surgeen2026-07-10T11:46:57.000ZChinese biotech MindRank secures $52m to advance AI-designed oral GLP-1RAhttps://www.pharmaradar360.com/article/developing-future-capability-starts-with-investing-in-people-d9e5f2e6171cfaf9Pharma Surgeen2026-07-10T11:26:43.000ZDeveloping future capability starts with investing in peoplehttps://www.pharmaradar360.com/article/five-reputable-pharmaceutical-packaging-machine-manufacturers-in-china-2026-adva-e5f78c7837c74de2Pharma Surgeen2026-07-10T11:20:44.000ZFive Reputable Pharmaceutical Packaging Machine Manufacturers in China 2026: Advancing Efficient Packaginghttps://www.pharmaradar360.com/article/okyo-s-urcosimod-gets-fda-nod-moves-to-global-phase-3-trial-for-ncp-e3ef06f6cd0c5a2ePharma Surgeen2026-07-10T11:13:34.000ZOKYO's urcosimod gets FDA nod, moves to global phase 3 trial for NCPhttps://www.pharmaradar360.com/article/non-profit-dndi-preps-phase-3-trials-for-dengue-antibody-02566cfbab034ee1Pharma Surgeen2026-07-10T11:08:19.000ZNon-profit DNDi preps phase 3 trials for dengue antibodyhttps://www.pharmaradar360.com/article/gsk-s-licensor-hansoh-pharma-announces-positive-phase-iii-results-for-ris-rez-in-d75ce56e167c69c3Pharma Surgeen2026-07-10T11:00:31.000ZGSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient populationhttps://www.pharmaradar360.com/article/decision-human-and-veterinary-medicines-register-of-licensed-manufacturing-sites-48cc8110c5fb4692Pharma Surgeen2026-07-10T10:59:20.000ZDecision: Human and veterinary medicines: register of licensed manufacturing siteshttps://www.pharmaradar360.com/article/notice-register-of-brokers-authorised-to-deal-in-human-medicines-e585a5b1747623a5Pharma Surgeen2026-07-10T10:59:07.000ZNotice: Register of brokers authorised to deal in human medicineshttps://www.pharmaradar360.com/article/decision-medicines-new-manufacturing-and-wholesale-dealer-licences-f98698f7dbd1470bPharma Surgeen2026-07-10T10:59:01.000ZDecision: Medicines: new manufacturing and wholesale dealer licenceshttps://www.pharmaradar360.com/article/decision-human-medicines-register-of-licensed-wholesale-distribution-sites-abe6f33fdfa7e172Pharma Surgeen2026-07-10T10:58:58.000ZDecision: Human medicines: register of licensed wholesale distribution siteshttps://www.pharmaradar360.com/article/notice-medicines-terminated-and-cancelled-manufacturing-and-wholesale-dealer-lic-b2bec9e140af5c62Pharma Surgeen2026-07-10T10:58:55.000ZNotice: Medicines: terminated and cancelled manufacturing and wholesale dealer licenceshttps://www.pharmaradar360.com/article/is-viking-therapeutics-stock-going-to-100-554c2b2bbbfc180fPharma Surgeen2026-07-10T10:57:55.000ZIs Viking Therapeutics Stock Going to $100?https://www.pharmaradar360.com/article/moderna-secures-up-to-24-million-rsv-vaccine-dose-contract-with-europe-df119d5e91ed0be6Pharma Surgeen2026-07-10T10:56:30.000ZModerna secures up to 24 million RSV vaccine dose contract with Europehttps://www.pharmaradar360.com/article/hansoh-pharmaceutical-pharma-announces-artemis-008-trial-of-risvutatug-rezetecan-4839c545a38faa78Pharma Surgeen2026-07-10T10:50:09.000ZHansoh Pharmaceutical : PHARMA ANNOUNCES ARTEMIS-008 TRIAL OF RISVUTATUG REZETECAN (HS-20093) MET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL IN SMALL CELL LUNG CANCERhttps://www.pharmaradar360.com/article/fda-criticizes-lundbeck-websites-are-false-or-misleading-02e72e332dd4ed4cPharma Surgeen2026-07-10T10:46:03.000ZFDA criticizes Lundbeck: Websites are “false or misleading”https://www.pharmaradar360.com/article/tobacco-and-vapes-packaging-appearance-and-display-b0f65b22298b2fc9Pharma Surgeen2026-07-10T10:45:08.000ZTobacco and vapes: packaging, appearance and displayhttps://www.pharmaradar360.com/article/standardised-packaging-for-all-tobacco-products-bf1d6af268a6e049Pharma Surgeen2026-07-10T10:45:08.000ZStandardised packaging for all tobacco productshttps://www.pharmaradar360.com/article/evonik-invests-100m-to-modernise-indiana-api-facility-505493fba91a4d94Pharma Surgeen2026-07-10T10:38:59.000ZEvonik invests $100m to modernise Indiana API facilityhttps://www.pharmaradar360.com/article/roche-canada-and-the-pan-canadian-pharmaceutical-alliance-pcpa-have-successfully-24368744f7bf4331Pharma Surgeen2026-07-10T10:37:04.000ZRoche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) have successfully completed negotiations for Itovebi® (inavolisib), a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutationhttps://www.pharmaradar360.com/article/5cda0bceb58dbe1fPharma Surgeen2026-07-10T10:24:27.000ZΠρόσκληση Εκδήλωσης Ενδιαφέροντος για σύσταση και στελέχωση της Επιτροπής Ελέγχου του Εθνικού Οργανισμού Φαρμάκων.https://www.pharmaradar360.com/article/pharmaceutical-drying-equipment-market-forecast-points-higher-toward-2035-driven-dbc7930f04b71ee6Pharma Surgeen2026-07-10T10:11:12.000ZPharmaceutical Drying Equipment Market Forecast Points Higher Toward 2035, Driven by Biologics Pipeline Expansionhttps://www.pharmaradar360.com/article/abivax-920-million-cash-haul-lets-it-prepare-for-solo-u-s-launch-instead-of-rely-bde11235ca7cbc53Pharma Surgeen2026-07-10T10:09:51.000ZAbivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBChttps://www.pharmaradar360.com/article/mdd-class-iii-surgipro-surgipro-ii-dermalon-v-loc-90-v-loc-180-ee4d78e6f552f6f4Pharma Surgeen2026-07-10T10:09:08.000ZΑνάκληση παρτίδων των Ιατροτεχνολογικών προϊόντων κατηγορίας MDD Class III, ραμμάτων Surgipro, Surgipro II, Dermalon, V-Loc 90 και V-Loc 180https://www.pharmaradar360.com/article/annovis-bio-nyse-anvs-completes-enrollment-in-850-patient-phase-3-alzheimer-s-st-cec90760bd3eeac9Pharma Surgeen2026-07-10T10:03:18.000ZAnnovis Bio (NYSE: ANVS) completes enrollment in 850-patient Phase 3 Alzheimer’s studyhttps://www.pharmaradar360.com/article/cordis-project-vascularized-next-generation-tumor-on-chip-for-adc-global-evaluat-7f399e19abad7c64Pharma Surgeen2026-07-10T09:54:34.000ZCORDIS project: Vascularized Next-Generation Tumor-on-Chip for ADC Global Evaluationhttps://www.pharmaradar360.com/article/anti-lag-3-with-or-without-anti-pd-1-in-recurrent-glioblastoma-a-phase-1-trial-2415429e47d23f35Pharma Surgeen2026-07-10T09:26:06.000ZAnti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trialhttps://www.pharmaradar360.com/article/roche-drops-two-huntington-s-programs-after-tominersen-miss-7a28f3bd454039dbPharma Surgeen2026-07-10T09:19:58.000ZRoche drops two Huntington’s programs after tominersen misshttps://www.pharmaradar360.com/article/doctor-at-ou-health-leads-new-clinical-trial-for-stage-1-lung-cancer-patients-4916613f488c7a16Pharma Surgeen2026-07-10T09:14:06.000ZDoctor at OU Health leads new clinical trial for stage 1 lung cancer patientshttps://www.pharmaradar360.com/article/five-reputable-pharmaceutical-packaging-machine-manufacturers-in-china-2026-adva-2320972a9dc01b4cPharma Surgeen2026-07-10T09:13:00.000ZFive Reputable Pharmaceutical Packaging Machine Manufacturers in China 2026: Advancing Efficient Packaging Solutionshttps://www.pharmaradar360.com/article/gattefosse-accelerates-production-ramp-up-at-its-lufkin-facility-with-eight-vali-2957905623c2f931Pharma Surgeen2026-07-10T09:12:06.000ZGattefossé accelerates production ramp-up at its Lufkin facility with eight validated ingredientshttps://www.pharmaradar360.com/article/human-capital-report-2026-85456b473f9cab77Pharma Surgeen2026-07-10T09:00:00.000Z人を生かす力が、未来を創る 社員とともに進める人的資本経営─Human Capital Report 2026発行のお知らせhttps://www.pharmaradar360.com/article/2026-a83acd67bf22a88bPharma Surgeen2026-07-10T08:58:14.000ZΓενόσημα Απριλίου 2026_Τελικές Προτεινόμενες Τιμέςhttps://www.pharmaradar360.com/article/4d391bbdaa31e7caPharma Surgeen2026-07-10T08:51:15.000ZΑΝΑΚΟΙΝΩΣΗ – ΔΙΑΚΟΠΗ ΗΛΕΚΤΡΟΝΙΚΩΝ ΥΠΗΡΕΣΙΩΝhttps://www.pharmaradar360.com/article/cspc-pharmaceutical-group-s-stock-price-soars-to-8-11-hkd-marking-a-robust-3-44-9c21bb729bb8c56ePharma Surgeen2026-07-10T08:41:03.000ZCSPC Pharmaceutical Group's Stock Price Soars to 8.11 HKD, Marking a Robust 3.44% Increasehttps://www.pharmaradar360.com/article/blood-tissue-and-organ-donors-surveillance-schemes-138d59cdd1f5d36dPharma Surgeen2026-07-10T08:30:02.000ZBlood, tissue and organ donors: surveillance schemeshttps://www.pharmaradar360.com/article/tetanus-in-england-annual-reports-55f6cea4b8ae62acPharma Surgeen2026-07-10T08:30:02.000ZTetanus in England: annual reportshttps://www.pharmaradar360.com/article/meningococcal-b-menb-time-limited-vaccination-offer-letter-72db639854c86c3cPharma Surgeen2026-07-10T08:30:02.000ZMeningococcal B (MenB) time limited vaccination offer letterhttps://www.pharmaradar360.com/article/hiv-yorkshire-and-humber-annual-data-spotlight-42ac168b52c26834Pharma Surgeen2026-07-10T08:30:02.000ZHIV: Yorkshire and Humber annual data spotlighthttps://www.pharmaradar360.com/article/bloodborne-infections-in-blood-tissue-and-organ-donors-bibd-guidance-data-and-an-326db28ff1cc42c9Pharma Surgeen2026-07-10T08:30:02.000ZBloodborne infections in blood, tissue and organ donors (BIBD): guidance, data and analysishttps://www.pharmaradar360.com/article/price-to-earnings-ratio-of-shaanxi-micot-pharmaceutical-technology-co-ltd-class-301908f0df855a2fPharma Surgeen2026-07-10T08:23:29.000ZPrice to earnings ratio of Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H – HKEX:2335https://www.pharmaradar360.com/article/pharmaceutical-3pl-market-size-share-growth-forecast-2034-b7de7ce36bdd3f1dPharma Surgeen2026-07-10T08:20:07.000ZPharmaceutical 3PL Market Size, Share | Growth Forecast [2034]https://www.pharmaradar360.com/article/price-to-sales-forward-of-beijing-sl-pharmaceutical-co-ltd-class-a-szse-002038-6838a881454d0f67Pharma Surgeen2026-07-10T08:18:56.000ZPrice to sales forward of Beijing SL Pharmaceutical Co. Ltd. Class A – SZSE:002038https://www.pharmaradar360.com/article/find-product-information-about-medicines-310bab551e083dcfPharma Surgeen2026-07-10T08:02:04.000ZFind product information about medicineshttps://www.pharmaradar360.com/article/3-psychedelic-stocks-with-potential-clinical-trial-catalysts-1da6f6918ebf402fPharma Surgeen2026-07-10T07:59:07.000Z3 Psychedelic Stocks With Potential Clinical Trial Catalystshttps://www.pharmaradar360.com/article/nagpur-fda-crackdown-indore-namkeen-products-food-licence-suspended-over-food-sa-7096a3b852ea937fPharma Surgeen2026-07-10T07:53:24.000ZNagpur FDA Crackdown: Indore Namkeen Products' Food Licence Suspended Over Food Safety Violationshttps://www.pharmaradar360.com/article/first-aid-a-new-idea-for-the-biotech-act-73f597158e4db8d7Pharma Surgeen2026-07-10T07:42:43.000ZFIRST AID: A new idea for the Biotech Acthttps://www.pharmaradar360.com/article/hanmi-pharm-s-phase-2-melanoma-trial-advances-as-planned-1a27dbc39612fb77Pharma Surgeen2026-07-10T07:05:07.000ZHanmi Pharm's phase 2 melanoma trial advances as plannedhttps://www.pharmaradar360.com/article/pharmequip-commits-to-deliver-high-performance-heat-exchange-solutions-for-austr-41f9872223d01899Pharma Surgeen2026-07-10T07:02:18.000ZPharmEquip Commits to Deliver High-Performance Heat Exchange Solutions for Australia's Pharmaceutical and Bioprocess Industrieshttps://www.pharmaradar360.com/article/we-have-better-antihistamines-0150ec4d101ff5b1Pharma Surgeen2026-07-10T07:00:00.000ZWe have better antihistamineshttps://www.pharmaradar360.com/article/oscotec-outlines-r-d-expansion-strategy-with-anti-resistance-cancer-platform-4e6fe69f7b76e066Pharma Surgeen2026-07-10T06:52:28.000ZOscotec outlines R&D expansion strategy with anti-resistance cancer platformhttps://www.pharmaradar360.com/article/cordis-project-digital-dashboards-in-diagnostic-innovations-98c7b78652f02f28Pharma Surgeen2026-07-10T06:50:39.000ZCORDIS project: DIGITAL DASHBOARDS IN DIAGNOSTIC INNOVATIONShttps://www.pharmaradar360.com/article/the-trial-without-walls-how-real-world-evidence-is-rewriting-the-rules-of-drug-a-043d6805a815b89bPharma Surgeen2026-07-10T06:48:45.000ZThe Trial Without Walls: How Real-World Evidence Is Rewriting the Rules of Drug Approvalhttps://www.pharmaradar360.com/article/astrazeneca-signs-potential-usd-1-9bn-deal-with-china-s-sino-dd9868a11c92d889Pharma Surgeen2026-07-10T06:38:13.000ZAstraZeneca signs potential USD 1.9bn deal with China's Sinohttps://www.pharmaradar360.com/article/ibt-portfolio-manager-biotech-m-a-boom-set-to-continue-as-big-pharma-hunts-55879e9982af78f6Pharma Surgeen2026-07-10T06:22:56.000ZIBT portfolio manager: biotech M&A boom set to continue as big pharma huntshttps://www.pharmaradar360.com/article/the-dawn-of-the-organoid-era-unveiling-the-silent-revolution-shaping-modern-biom-949c3b5c2dff8487Pharma Surgeen2026-07-10T06:21:51.000ZThe Dawn of the Organoid Era: Unveiling the Silent Revolution Shaping Modern Biomedical Sciencehttps://www.pharmaradar360.com/article/3-psychedelic-stocks-with-potential-clinical-trial-catalysts-72e186112040e2afPharma Surgeen2026-07-10T06:21:00.000Z3 Psychedelic Stocks With Potential Clinical Trial Catalystshttps://www.pharmaradar360.com/article/biotech-cameras-make-roads-safer-fd55bd952b675769Pharma Surgeen2026-07-10T06:13:23.000ZBiotech Cameras Make Roads Saferhttps://www.pharmaradar360.com/article/us-s-biotech-scrutiny-tests-china-s-drugmakers-abroad-d54d9f9bc91ea8e7Pharma Surgeen2026-07-10T06:07:22.000ZUS’s biotech scrutiny tests China’s drugmakers abroadhttps://www.pharmaradar360.com/article/hlb-liver-cancer-drug-hits-fda-setback-again-over-manufacturing-issues-c4920f757f0e2a62Pharma Surgeen2026-07-10T05:54:38.000ZHLB liver cancer drug hits FDA setback again over manufacturing issueshttps://www.pharmaradar360.com/article/waycen-partners-with-daewoong-to-expand-ai-endoscopy-market-eb15a977afb1b1dePharma Surgeen2026-07-10T05:44:54.000ZWaycen partners with Daewoong to expand AI endoscopy markethttps://www.pharmaradar360.com/article/abobotulinumtoxina-meets-primary-end-points-in-phase-3-program-for-both-episodic-d645061362f3736dPharma Surgeen2026-07-10T05:37:04.000ZAbobotulinumtoxinA Meets Primary End Points in Phase 3 Program for Both Episodic and Chronic Migrainehttps://www.pharmaradar360.com/article/oncolytics-biotech-nasdaq-oncy-shares-up-16-1-what-s-next-2aba87ea3f453c20Pharma Surgeen2026-07-10T04:22:40.000ZOncolytics Biotech (NASDAQ:ONCY) Shares Up 16.1% - What's Next?https://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-amchepry-9b2c6c6fbacbbd29Pharma Surgeen2026-07-10T03:00:00.000Z[SHINSA]English Translation of Review Report: AMCHEPRYhttps://www.pharmaradar360.com/article/kokusai-pmda-updates-2026-no-2-posted-080e4a2b9cea0830Pharma Surgeen2026-07-10T03:00:00.000Z[KOKUSAI]PMDA Updates (2026 No.2) postedhttps://www.pharmaradar360.com/article/price-to-sales-forward-of-rtw-biotech-opportunities-ltd-usd-swb-0bm-f223477db0ccc54ePharma Surgeen2026-07-10T02:48:26.000ZPrice to sales forward of RTW Biotech Opportunities Ltd USD – SWB:0BMhttps://www.pharmaradar360.com/article/the-90-problem-why-most-biotech-assets-fail-c4750819378fc1e7Pharma Surgeen2026-07-10T02:20:15.000ZThe 90% Problem: Why Most Biotech Assets Failhttps://www.pharmaradar360.com/article/hlb-receives-fda-crl-for-rivoceranib-as-manufacturing-issues-delay-approval-ef62659cb9aa38c5Pharma Surgeen2026-07-10T02:05:28.000ZHLB Receives FDA CRL for Rivoceranib as Manufacturing Issues Delay Approvalhttps://www.pharmaradar360.com/article/hlb-plunges-to-daily-limit-as-fda-issues-third-rejection-for-liver-cancer-drug-g-fc72b742efb218aaPharma Surgeen2026-07-10T01:55:00.000ZHLB Plunges to Daily Limit as FDA Issues Third Rejection for Liver Cancer Drug; Group Stocks Wiped Outhttps://www.pharmaradar360.com/article/zhangjiang-pharma-valley-fuels-biotech-momentum-2d9713df745c260bPharma Surgeen2026-07-10T01:50:11.000ZZhangjiang Pharma Valley fuels biotech momentumhttps://www.pharmaradar360.com/article/astrazeneca-heart-drug-misses-phase-3-goal-as-design-woes-sink-shares-chosunbiz-a25e8cfd96d0ce1cPharma Surgeen2026-07-10T00:51:00.000ZAstraZeneca heart drug misses phase 3 goal as design woes sink shares - CHOSUNBIZhttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-5ef9e899659d7af2Pharma Surgeen2026-07-10T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/the-history-of-the-petro-petros-love-at-first-bite-a72ab912393b47b7Pharma Surgeen2026-07-10T00:00:00.000ZThe History of the Petro® — Petros® Love at First Bitehttps://www.pharmaradar360.com/article/menu-petros-chili-chips-love-at-first-bite-petros-love-at-first-bite-80b8d50385b95e20Pharma Surgeen2026-07-10T00:00:00.000ZMenu | Petros Chili & Chips — Love at First Bite — Petros® Love at First Bitehttps://www.pharmaradar360.com/article/loyalty-rewards-petros-chili-chips-petros-love-at-first-bite-3843ae603e8f6650Pharma Surgeen2026-07-10T00:00:00.000ZLoyalty Rewards | Petros Chili & Chips — Petros® Love at First Bitehttps://www.pharmaradar360.com/article/petros-love-at-first-bite-7b40927ecf3ad8d6Pharma Surgeen2026-07-10T00:00:00.000ZPetros® Love at First Bitehttps://www.pharmaradar360.com/article/cater-with-petro-s-petros-love-at-first-bite-70eb697b4f96918aPharma Surgeen2026-07-10T00:00:00.000ZCater with Petro's! — Petros® Love at First Bitehttps://www.pharmaradar360.com/article/otsuka-pharmaceutical-factory-announces-expansion-of-iv-solutions-manufacturing-c0acab21aec7cb80Pharma Surgeen2026-07-10T00:00:00.000ZOtsuka Pharmaceutical Factory Announces Expansion of IV Solutions Manufacturing Capacity in North America Advancing Supply Stability and Development of DEHP-Free IV Containershttps://www.pharmaradar360.com/article/timothy-genetta-d-o-decision-and-order-858014d7ff7959bcPharma Surgeen2026-07-10T00:00:00.000ZTimothy Genetta, D.O.; Decision and Orderhttps://www.pharmaradar360.com/article/ruth-jones-d-o-decision-and-order-7376c48cad3f11b5Pharma Surgeen2026-07-10T00:00:00.000ZRuth Jones, D.O.; Decision and Orderhttps://www.pharmaradar360.com/article/mariana-moualem-f-n-p-decision-and-order-0b95a1f3dc6288bfPharma Surgeen2026-07-10T00:00:00.000ZMariana Moualem, F.N.P.; Decision and Orderhttps://www.pharmaradar360.com/article/mark-allen-d-d-s-decision-and-order-6ee03d311a438c8dPharma Surgeen2026-07-10T00:00:00.000ZMark Allen, D.D.S.; Decision and Orderhttps://www.pharmaradar360.com/article/frederick-tanzer-m-d-decision-and-order-b2ce0b41c792a214Pharma Surgeen2026-07-10T00:00:00.000ZFrederick Tanzer, M.D.; Decision and Orderhttps://www.pharmaradar360.com/article/charter-re-establishment-for-the-national-advisory-committee-on-rural-health-and-bf3aeb8cf92cae87Pharma Surgeen2026-07-10T00:00:00.000ZCharter Re-Establishment for the National Advisory Committee on Rural Health and Human Serviceshttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-national-human-trafficking-62bd316879dfceacPharma Surgeen2026-07-10T00:00:00.000ZSubmission for Office of Management and Budget Review; National Human Trafficking Training and Technical Assistance Center Evaluation Packagehttps://www.pharmaradar360.com/article/meeting-of-the-advisory-board-on-radiation-and-worker-health-national-institute-aa80b564b17b64a8Pharma Surgeen2026-07-10T00:00:00.000ZMeeting of the Advisory Board on Radiation and Worker Health, National Institute for Occupational Safety and Healthhttps://www.pharmaradar360.com/article/medicare-and-medicaid-programs-application-from-the-joint-commission-for-continu-36896811c8ee47c5Pharma Surgeen2026-07-10T00:00:00.000ZMedicare and Medicaid Programs; Application From The Joint Commission for Continued CMS Approval of Its Home Health Agency (HHA) Accreditation Programhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-public-comment-requ-964b4c71713a2f8dPharma Surgeen2026-07-10T00:00:00.000ZAgency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Healthy Start Evaluation and Quality Improvement, OMB No. 0915-0338-Revisionhttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-income-withholding-for-sup-ac0c6109c09ec6ddPharma Surgeen2026-07-10T00:00:00.000ZSubmission for Office of Management and Budget Review; Income Withholding for Supporthttps://www.pharmaradar360.com/article/why-passive-activities-can-be-bad-for-your-brain-ab97ca10f74ef8d8Pharma Surgeen2026-07-10T00:00:00.000ZWhy Passive Activities Can be Bad for Your Brainhttps://www.pharmaradar360.com/article/fda-actions-to-support-and-strengthen-domestic-drug-manufacturing-1b89547079376e32Pharma Surgeen2026-07-10T00:00:00.000ZFDA Actions to Support and Strengthen Domestic Drug Manufacturinghttps://www.pharmaradar360.com/article/integrating-causal-inference-into-pharmacovigilance-target-trial-emulations-for-94a57279469639cdPharma Surgeen2026-07-10T00:00:00.000ZIntegrating Causal Inference into Pharmacovigilance: Target Trial Emulations for Proactive Signal Detection of Atorvastatin Initiation in Medicare Beneficiarieshttps://www.pharmaradar360.com/article/topical-latanoprost-acid-for-female-androgenetic-alopecia-a-pilot-proof-of-conce-8c186a878abb4146Pharma Surgeen2026-07-10T00:00:00.000ZTopical latanoprost acid for female androgenetic alopecia: a pilot proof-of-concept trial with mechanistic evidence of prostaglandin F2α receptor activation.https://www.pharmaradar360.com/article/sex-differences-in-stress-responding-in-a-randomized-placebo-controlled-clinical-3edec6d87ca0843bPharma Surgeen2026-07-10T00:00:00.000ZSex differences in stress responding in a randomized, placebo-controlled clinical trial of progesterone in cannabis use disorder.https://www.pharmaradar360.com/article/comparison-of-quantitative-prediction-methods-for-drug-drug-interactions-based-o-5f3c57e5c5d5e3edPharma Surgeen2026-07-10T00:00:00.000ZComparison of Quantitative Prediction Methods for Drug–Drug Interactions Based on Cytochrome P450 Inhibitionhttps://www.pharmaradar360.com/article/the-nurse-role-in-early-mobilization-in-icu-a-brazilian-perspective-on-recovery-2d86f797c817470bPharma Surgeen2026-07-10T00:00:00.000ZThe nurse role in early mobilization in ICU: A Brazilian perspective on recovery-oriented critical carehttps://www.pharmaradar360.com/article/socio-demographic-clinical-and-household-environmental-profiles-of-visceral-and-3b1038d1e9c4df95Pharma Surgeen2026-07-10T00:00:00.000ZSocio-Demographic, Clinical, and Household Environmental Profiles of Visceral and Cutaneous Leishmaniasis Cases in Keekonyokie Ward, Kajiado West Sub-County, Kenyahttps://www.pharmaradar360.com/article/unmet-needs-and-polypharmacy-as-key-drivers-of-drug-therapy-problems-among-cardi-f344f2bb6b401560Pharma Surgeen2026-07-10T00:00:00.000ZUnmet needs and polypharmacy as key drivers of drug therapy problems among cardiac patients at a tertiary hospital: a cross-sectional studyhttps://www.pharmaradar360.com/article/vsl-3-may-reduce-abdominal-pain-and-bloating-in-ulcerative-colitis-remission-wit-4c9f59e6ff5a8d29Pharma Surgeen2026-07-10T00:00:00.000ZVSL#3® May Reduce Abdominal Pain and Bloating in Ulcerative Colitis Remission with IBS-like Symptoms: An Exploratory Randomized, Double-Blind Placebo-Controlled Trialhttps://www.pharmaradar360.com/article/magnesium-sulfate-gargle-for-preventing-postoperative-sore-throat-following-lary-71cc06da6884b6f3Pharma Surgeen2026-07-10T00:00:00.000ZMagnesium sulfate gargle for preventing postoperative sore throat following laryngeal mask airway ventilation: a randomized, controlled, dose-finding trialhttps://www.pharmaradar360.com/article/clinical-characteristics-and-cytokine-profiles-for-early-prediction-of-severe-my-8c31606bac781161Pharma Surgeen2026-07-10T00:00:00.000ZClinical characteristics and cytokine profiles for early prediction of severe Mycoplasma pneumoniae pneumonia in children: a prospective cohort studyhttps://www.pharmaradar360.com/article/therapeutic-plasma-exchange-as-a-bridge-to-thyroidectomy-in-refractory-amiodaron-89a8381ebd2c4244Pharma Surgeen2026-07-10T00:00:00.000ZTherapeutic plasma exchange as a bridge to thyroidectomy in refractory amiodarone- induced thyrotoxicosis – Case Reporthttps://www.pharmaradar360.com/article/a-study-of-the-utilization-pattern-of-antihypertensive-drugs-in-a-tertiary-care-c62d90c6ca77c568Pharma Surgeen2026-07-10T00:00:00.000ZA Study of the Utilization Pattern of Antihypertensive Drugs in a Tertiary Care Teaching Hospitalhttps://www.pharmaradar360.com/article/a-retrospective-analysis-of-skin-biopsies-over-one-year-age-sex-distribution-and-ba8a16b36ad1f373Pharma Surgeen2026-07-10T00:00:00.000ZA Retrospective Analysis of Skin Biopsies Over One Year: Age, Sex Distribution, and Histopathological Patternshttps://www.pharmaradar360.com/article/analysis-of-acute-kidney-injury-in-patients-with-sepsis-under-icu-03560292f45fe2caPharma Surgeen2026-07-10T00:00:00.000ZAnalysis of Acute Kidney Injury in Patients with Sepsis Under ICUhttps://www.pharmaradar360.com/article/assessment-of-nutritional-status-and-morbidity-pattern-in-children-aged-6-60-mon-3bf5b9f0bdb5846ePharma Surgeen2026-07-10T00:00:00.000ZAssessment of Nutritional Status and Morbidity Pattern in Children Aged 6–60 Months in the Rural Area Patnahttps://www.pharmaradar360.com/article/clinical-profile-and-outcomes-of-patients-with-heart-failure-with-preserved-and-b928b0c1af01a8fcPharma Surgeen2026-07-10T00:00:00.000ZClinical Profile and Outcomes of Patients with Heart Failure with Preserved and Reduced Ejection Fraction